First Time Loading...

Y-mAbs Therapeutics Inc
NASDAQ:YMAB

Watchlist Manager
Y-mAbs Therapeutics Inc Logo
Y-mAbs Therapeutics Inc
NASDAQ:YMAB
Watchlist
Price: 16.5 USD 5.1% Market Closed
Updated: Mar 28, 2024

Intrinsic Value

YMAB's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer. [ Read More ]

The intrinsic value of one YMAB stock under the Base Case scenario is 21.68 USD. Compared to the current market price of 16.5 USD, Y-mAbs Therapeutics Inc is Undervalued by 24%.

Key Points:
YMAB Intrinsic Value
Base Case
21.68 USD
Undervaluation 24%
Intrinsic Value
Price
Base Case Scenario

Valuation Backtest
Y-mAbs Therapeutics Inc

Backtest YMAB Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling YMAB stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

How can I assist you today?

Provide an overview
of Y-mAbs Therapeutics Inc's business.

What risks and challenges
does Y-mAbs Therapeutics Inc face in the near future?

Summarize the latest earnings report
of Y-mAbs Therapeutics Inc.

Provide P/E
for Y-mAbs Therapeutics Inc and its competitors.

Financials

Balance Sheet Decomposition
Y-mAbs Therapeutics Inc

Current Assets 111.1m
Cash & Short-Term Investments 78.6m
Receivables 22.5m
Other Current Assets 10m
Non-Current Assets 16.8m
PP&E 1.6m
Intangibles 2.6m
Other Non-Current Assets 12.5m
Current Liabilities 20.1m
Accounts Payable 6.1m
Accrued Liabilities 14.1m
Non-Current Liabilities 6.8m
Other Non-Current Liabilities 6.8m
Efficiency

Earnings Waterfall
Y-mAbs Therapeutics Inc

Revenue
84.8m USD
Cost of Revenue
-11.4m USD
Gross Profit
73.5m USD
Operating Expenses
-94.6m USD
Operating Income
-21.2m USD
Other Expenses
-237k USD
Net Income
-21.4m USD

Free Cash Flow Analysis
Y-mAbs Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

YMAB Profitability Score
Profitability Due Diligence

Y-mAbs Therapeutics Inc's profitability score is 34/100. The higher the profitability score, the more profitable the company is.

34/100
Profitability
Score

Y-mAbs Therapeutics Inc's profitability score is 34/100. The higher the profitability score, the more profitable the company is.

YMAB Solvency Score
Solvency Due Diligence

Y-mAbs Therapeutics Inc's solvency score is 68/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Low D/E
Average Altman Z-Score
68/100
Solvency
Score

Y-mAbs Therapeutics Inc's solvency score is 68/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

YMAB Price Targets Summary
Y-mAbs Therapeutics Inc

Wall Street analysts forecast YMAB stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for YMAB is 20.4 USD with a low forecast of 10.1 USD and a high forecast of 27.3 USD.

Lowest
Price Target
10.1 USD
39% Downside
Average
Price Target
20.4 USD
24% Upside
Highest
Price Target
27.3 USD
65% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

YMAB Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

YMAB Price
Y-mAbs Therapeutics Inc

1M 1M
+1%
6M 6M
+196%
1Y 1Y
+431%
3Y 3Y
-43%
5Y 5Y
-27%
10Y 10Y
-31%
Annual Price Range
16.5
52w Low
3.11
52w High
18.69
Price Metrics
Average Annual Return -9.93%
Standard Deviation of Annual Returns 68.61%
Max Drawdown -95%
Shares Statistics
Market Capitalization 720.6m USD
Shares Outstanding 43 777 100
Percentage of Shares Shorted 5.96%

YMAB Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Y-mAbs Therapeutics Inc Logo
Y-mAbs Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

720.6m USD

Dividend Yield

0%

Description

Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer. The company is headquartered in New York City, New York and currently employs 148 full-time employees. The company went IPO on 2018-09-21. The company is focused on development and commercialization of antibody based therapeutic products for the treatment of cancer. The Company’s technologies include bispecific antibodies generated using the Y-BiClone platform and the SADA platform. The Company’s product pipeline includes DANYELZA (naxitamab-gqgk), which targets tumors that express GD2, and omburtamab, which targets tumors that express B7-H3. DANYELZA, which is a humanized monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment of in the bone or bone marrow stable disease to prior therapy and being evaluated for the treatment of other GD2-positive tumors. The company also develops Omburtamab, which is novel murine monoclonal antibody targeting B7-H3. The firm is conducting Phase II clinical trials for the treatment of patients with first-line NB, third-line NB, and in relapsed osteosarcoma.

Contact

NEW YORK
New York City
230 Park Avenue, Suite 3350
+12128479841.0
https://www.ymabs.com/

IPO

2018-09-21

Employees

148

Officers

Founder, Chief Business Officer & Vice Chairman
Mr. Thomas Gad
Executive VP, Secretary, Treasurer & CFO
Mr. Bo Kruse
Senior VP & Chief Commercial Officer
Ms. Susan Smith
CEO, President & Director
Mr. Michael Rossi
Senior VP & COO
Mr. Joris Wiel Jan Wilms
Senior VP & CTO
Dr. Torben Lund-Hansen M.Sc., Ph.D.
Show More
Senior VP & Chief Scientific Officer
Dr. Steen Lisby M.D., M.Sc.
Senior VP & Chief Medical Officer
Dr. Vignesh Rajah M.B.A., MBBS
Show Less

See Also

Discover More
What is the Intrinsic Value of one YMAB stock?

The intrinsic value of one YMAB stock under the Base Case scenario is 21.68 USD.

Is YMAB stock undervalued or overvalued?

Compared to the current market price of 16.5 USD, Y-mAbs Therapeutics Inc is Undervalued by 24%.